Ovarian cancer clue: Methylation-mediated suppression of a key pathway is found

December 13, 2010

December 14, 2010 - Ovarian cancer is the leading cause of death among gynecological cancers. To better understand the disease and improve therapies, researchers are investigating how deregulation of genes across the genome could be contributing to malignancy. In a study published online today in Genome Research (www.genome.org), scientists have identified age-related gene-specific accumulation of DNA methylation that suppresses a critical cellular pathway contributing to ovarian carcinogenesis, information that will be crucial for future translational research.

Epigenetic silencing of genes by a chemical modification called DNA methylation is known to play a role in the development of malignancies such as ovarian cancer by turning off genes that normally suppress tumor growth. Yet the scope of DNA methylation across the entire cancer genome is not well understood, hindering efforts to understand the biological basis of the disease.

In this study, an international team of researchers from the United States and Japan performed a genome-wide analysis of gene expression in ovarian cancer by transcriptome profiling, looking for genes silenced by DNA methylation that might be involved in the disease. The research group analyzed gene expression in established ovarian cancer cell lines and primary cultured ovarian cancer cells that were either mock treated, or treated with a chemical agent that blocks DNA methylation.

This strategy identified 378 candidate methylated genes in ovarian cancers. When the group began investigating the functions of the genes subject to methylation in the malignancies, an intriguing clue to the biology of ovarian cancer arose from the list.

"While we hoped to identify a substantial group of candidate methylated genes," said researcher Susan Murphy of Duke University Medical Center and senior author of the study, "we did not anticipate that we would find methylation-mediated deregulation of many genes involved in a specific functional pathway, the TGF-beta pathway."

The TGF-beta pathway is a cellular signaling network that controls cell growth and differentiation, normally curbing tumor growth, but can promote cancer when disrupted. This work reports for the first time that methylation of genes in the TGF-beta superfamily suppresses the TGF-beta pathway in ovarian cancer. Murphy and colleagues also observed that methylation increased with patient age, suggesting that gene-specific methylation accumulates over time.

Murphy added that the methylated genes identified in this study will aid in the design of new strategies to treat the disease. "Knowing the identity of these genes provides for the ability to carry out focused studies to understand their specific role in ovarian cancer," Murphy explained, "and may present opportunities for targeted therapeutic interventions."
Scientists from Duke University (Durham, NC), Kyoto University (Kyoto, Japan), and the National Hospital Organization Kyoto Medical Center (Kyoto, Japan) contributed to this study.

This work was supported by the Department of Defense CDMRP Ovarian Cancer Research Program and a grant from the Japan Society for the Promotion of Science.

Media contacts:

The authors are available for more information by contacting Mary Jane Gore, Senior Science Writer, Duke Medicine News and Communications (+1-919-660-1309; mary.gore@duke.edu).

Interested reporters may obtain copies of the manuscript from Peggy Calicchia, Editorial Secretary, Genome Research (calicchi@cshl.edu; +1-516-422-4012).

About the article:

The manuscript will be published online ahead of print on December 14, 2010. Its full citation is as follows: Matsumura N, Huang Z, Mori S, Baba T, Fujii S, Konishi I, Iversen ES, Berchuck A, Murphy SK. Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer. Genome Res doi:10.1101/gr.108803.110.

About Genome Research:

Launched in 1995, Genome Research (www.genome.org) is an international, continuously published, peer-reviewed journal that focuses on research that provides novel insights into the genome biology of all organisms, including advances in genomic medicine. Among the topics considered by the journal are genome structure and function, comparative genomics, molecular evolution, genome-scale quantitative and population genetics, proteomics, epigenomics, and systems biology. The journal also features exciting gene discoveries and reports of cutting-edge computational biology and high-throughput methodologies.

About Cold Spring Harbor Laboratory Press:

Cold Spring Harbor Laboratory is a private, nonprofit institution in New York that conducts research in cancer and other life sciences and has a variety of educational programs. Its Press, originating in 1933, is the largest of the Laboratory's five education divisions and is a publisher of books, journals, and electronic media for scientists, students, and the general public.

Genome Research issues press releases to highlight significant research studies that are published in the journal.

Cold Spring Harbor Laboratory

Related Ovarian Cancer Articles from Brightsurf:

Ovarian cancer cells cooperate to metastasize
In a study on human ovarian cancer cells in mice, Harvard Medical School researchers discovered a transient, cooperative interaction between cell subpopulations that allows otherwise nonmetastatic tumor cells to become aggressive and spread.

Photodynamic therapy used to treat ovarian cancer
Photodynamic therapy (PDT) is one of the most promising methods of treating localized tumors.

Studying the development of ovarian cancer with organoids
Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade serous ovarian cancer in mini-versions, or organoids, of the female reproductive organs of the mouse.

New class of drugs could treat ovarian cancer
A team of researchers across the University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing.

How to catch ovarian cancer earlier
Ovarian cancer is often diagnosed too late for effective treatment.

New compound could help treat ovarian cancer
Scientists from the University of Sheffield have discovered a compound that could be more effective in treating certain cancers than standard chemotherapy.

Epigenetic markers of ovarian cancer
Insilico Medicine and its collaborators from Johns Hopkins and Insilico Medicine, used an integrated approach by coupling identification of genome-wide expression patterns in multiple cohorts of primary ovarian cancer samples and normal ovarian surface epithelium with innovative computational analysis of gene expression data, leading to the discovery of novel cancer-specific epigenetically silenced genes.

Ovarian cancer statistics, 2018
A new report from the American Cancer Society provides an overview of ovarian cancer occurrence and mortality data.

Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.

TGen-led study finds potent anti-cancer drug effect in rare ovarian cancer
An anti-cancer drug used to fight leukemia shows promise against a rare and aggressive type of ovarian cancer -- small cell carcinoma of the ovary hypercalcemic type (SCCOHT) -- which strikes young women and girls, according to a study led by the TGen.

Read More: Ovarian Cancer News and Ovarian Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.